-
Product Insights
Pneumonia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Pneumonia Clinical Trial Analysis research report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials.
-
Sector Analysis
Allergic Rhinitis Immunotherapy - Opportunity Analysis and Forecasts to 2028
Allergic rhinitis (AR) is a common, IgE-mediated inflammatory disease in which an individual reacts to an otherwise innocuous inhaled substance in the environment with one or more of the following symptoms: rhinorrhea, sneezing, nasal congestion, and pruritus of the eyes, nose, and palate. Based on epidemiological analysis by GlobalData, in 2018 there were over 70.5M 12-month diagnosed prevalent cases of AR among adults and adolescents throughout the seven major pharmaceutical markets (7MM) covered in this report, the US, 5EU (France,...
-
Sector Analysis
Cystic Fibrosis – Global Drug Forecast and Market Analysis to 2030
The global (7MM) sales for the cystic fibrosis (CF) have been valued at $8.2 billion in 2020. The market is expected to grow at a CAGR of more than 4% during 2021-2025. Over the past decade, there have been significant changes in the CF market due to the development of CFTR modulator therapies that target the underlying cause of CF. Most of the sales has come from the US, which represents more than 75% of the market by 2030. The...
-
Sector Analysis
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025
The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF – Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 (Event Driven Update)
Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule...
-
Sector Analysis
Asthma - Global Drug Forecast and Market Analysis to 2029
Asthma Market Report Overview The asthma market size across the 7MM was $9.7 billion in 2019 and will achieve a CAGR of more than 1% during 2019-2029. Asthma is a common chronic lung disease characterized by chronic inflammation and subsequent narrowing of the airways that most often develops during childhood but can occur at any age. It can be persistent or intermittent and varies by severity. The symptoms of asthma are often triggered by factors such as exercise, allergen or...
-
Sector Analysis
Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2028
Chronic obstructive pulmonary disease (COPD) is a common, preventable, incurable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation. Long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution can induce chronic inflammation in the airways, subsequently causing alveolar abnormalities. Pro-inflammatory cytokines, which are secreted from immune cells such as neutrophils, macrophages, and B cells, and CD4+ and CD8+ T lymphocyte infiltration in the lungs, in addition to elastases, can cause destruction...
-
Sector Analysis
PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough,...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029
Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule...
-
Sector Analysis
OpportunityAnalyzer: Cystic Fibrosis – Opportunity Analysis and Forecasts to 2025
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR protein. As a multisystem condition, CF patients show great heterogeneity in presenting clinical symptoms. CF mainly affects the respiratory and gastrointestinal tracts. Three classes of drugs have been used to for treatment in CF patients: inhaled antibiotics for bacterial and fungal respiratory infections, mucolytic drugs for mucociliary clearance of the airways, and pancreatic enzyme replacement...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.